05.01.15
Isis Pharmaceuticals, Inc. has earned a $10 million milestone payment from Biogen associated with the validation of an undisclosed target to treat a neurological disorder. This is the ninth program to advance under the strategic alliance, which includes four drugs in development to treat neurological and neuromuscular disorders. To date, Isis has earned $329 million in payments from Biogen.
"Together with Biogen, we have made significant progress advancing multiple programs. In our pipeline, we have four drugs in development with Biogen, including ISIS-SMNRx, ISIS-DMPK-2.5Rx and two drugs to undisclosed targets. In addition, we have a number of earlier stage programs, like this one, that we will be advancing this year," said B. Lynne Parshall, chief operating officer at Isis Pharmaceuticals.
"Together with Biogen, we have made significant progress advancing multiple programs. In our pipeline, we have four drugs in development with Biogen, including ISIS-SMNRx, ISIS-DMPK-2.5Rx and two drugs to undisclosed targets. In addition, we have a number of earlier stage programs, like this one, that we will be advancing this year," said B. Lynne Parshall, chief operating officer at Isis Pharmaceuticals.